3:30 AM
 | 
Apr 03, 2019
 |  BioCentury  |  Finance

The dynamics of Dyne

How Atlas start-up Dyne plans to use nucleic acids to treat rare muscle diseases

Editor's Note: This article was updated on Apr 05, 2019 at 10:51 AM PDT

Incubated by Atlas Venture and launched Wednesday with a $50 million series A round, Dyne Therapeutics Inc. is using its muscle-targeting platform to develop therapies for rare diseases, beginning with myotonic dystrophy type 1 (DM1).

As it develops its own pipeline, the company could also in parallel seek partnerships based on its platform, potentially in cardiac indications, Atlas' Jason Rhodes told BioCentury.

MPM Capital and Forbion Capital Partners joined Atlas in backing Dyne, which is developing its FORCE platform to deliver nucleic acids specifically into muscle. FORCE uses antibody conjugates to deliver the molecules, minimizing systemic...

Read the full 457 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >